Characteristic genomic imbalances and comparison of frequencies among DLBCL subgroups
. | . | . | . | . | . | . | Fisher P . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Chromosome . | Gain/loss . | Minimum common region . | ABC, no. cases (%) . | GCB, no. cases (%) . | CD5+, no. cases (%) . | CD5−CD10+, no. cases (%) . | ABC vs GCB . | CD5+ vs CD10+ . | |
| 1 | Gain | 1q21.1-q23.3 | 0 (0) | 8 (44) | 6-7 (17-19) | 5-7 (26-37) | < .01 | NS | |
| 1 | Gain | 1q31.1-q42.13 | 2 (0-7) | 8-9 (44-50) | 5-6 (14-17) | 6-7 (32-37) | < .01 | NS | |
| 2 | Gain | 2p15-p16.1 | 2 (7) | 6 (33) | 4-8 (11-22) | 5-8 (26-42) | .04 | NS | |
| 3 | Gain | 3q23-q28 | 7-10 (25-36) | 0 (0) | 11 (31) | 0-1 (0-5) | .03 | .01-.04 | |
| 6 | Loss | 6q22.31-q24.1 | 11-13 (39-46) | 2 (11) | 16 (44) | 12 (63) | .02-.04 | NS | |
| 7 | Gain | 7q22.1-q36.2 | 1 (4) | 9-11 (50-61) | 4-6 (11-17) | 9-11 (47-58) | < .01 | < .01 | |
| 9 | Loss | 9p21.3 | 19 (68) | 5 (28) | 18 (50) | 4 (21) | .01 | .04 | |
| 12 | Gain | 12q13.13-q14.1 | 4 (14) | 8 (44) | 5-6 (14-17) | 9-13 (47-68) | .04 | < .02 | |
| 17 | Gain | 17p13.1 | 5 (18) | 3 (17) | 2 (6) | 7 (37) | NS | < .01 | |
| 18 | Gain | 18q11.2-q23 | 13-15 (46-54) | 3-4 (17-22) | 14-15 (38-42) | 5 (26) | .03 | NS | |
| 19 | Gain | 19q13.32-q13.33 | 13 (46) | 3 (17) | 12 (33) | 12 (63) | NS | NS | |
| 19 | Gain | 19q13.41-q13.42 | 15 (54) | 3 (17) | 17 (47) | 12 (63) | .01 | NS | |
. | . | . | . | . | . | . | Fisher P . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Chromosome . | Gain/loss . | Minimum common region . | ABC, no. cases (%) . | GCB, no. cases (%) . | CD5+, no. cases (%) . | CD5−CD10+, no. cases (%) . | ABC vs GCB . | CD5+ vs CD10+ . | |
| 1 | Gain | 1q21.1-q23.3 | 0 (0) | 8 (44) | 6-7 (17-19) | 5-7 (26-37) | < .01 | NS | |
| 1 | Gain | 1q31.1-q42.13 | 2 (0-7) | 8-9 (44-50) | 5-6 (14-17) | 6-7 (32-37) | < .01 | NS | |
| 2 | Gain | 2p15-p16.1 | 2 (7) | 6 (33) | 4-8 (11-22) | 5-8 (26-42) | .04 | NS | |
| 3 | Gain | 3q23-q28 | 7-10 (25-36) | 0 (0) | 11 (31) | 0-1 (0-5) | .03 | .01-.04 | |
| 6 | Loss | 6q22.31-q24.1 | 11-13 (39-46) | 2 (11) | 16 (44) | 12 (63) | .02-.04 | NS | |
| 7 | Gain | 7q22.1-q36.2 | 1 (4) | 9-11 (50-61) | 4-6 (11-17) | 9-11 (47-58) | < .01 | < .01 | |
| 9 | Loss | 9p21.3 | 19 (68) | 5 (28) | 18 (50) | 4 (21) | .01 | .04 | |
| 12 | Gain | 12q13.13-q14.1 | 4 (14) | 8 (44) | 5-6 (14-17) | 9-13 (47-68) | .04 | < .02 | |
| 17 | Gain | 17p13.1 | 5 (18) | 3 (17) | 2 (6) | 7 (37) | NS | < .01 | |
| 18 | Gain | 18q11.2-q23 | 13-15 (46-54) | 3-4 (17-22) | 14-15 (38-42) | 5 (26) | .03 | NS | |
| 19 | Gain | 19q13.32-q13.33 | 13 (46) | 3 (17) | 12 (33) | 12 (63) | NS | NS | |
| 19 | Gain | 19q13.41-q13.42 | 15 (54) | 3 (17) | 17 (47) | 12 (63) | .01 | NS | |
For ABC, n = 28; for GCB, n = 18; for CD5+, n = 36; for CD5−CD10+, n = 19.
NS indicates not significant; no. cases, the number of cases showing genomic gains and losses within each minimum common region.